Literature DB >> 25636447

Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer.

Chun-Hua Xu1, Lan Cao, Xiu-Wei Zhang, Jun Yan, Li-Ke Yu.   

Abstract

B7-H4, a member of the inhibitory B7 family, can restrain T cell proliferation, activation, and cytokine secretion and may be involved in immune evasion in cancer patients. This study aimed to evaluate the diagnostic and prognostic value of pleural effusion levels of soluble B7-H4 (sB7-H4) in lung cancer patients with malignant pleural effusion (MPE). Pleural effusion samples were collected from 98 lung cancer patients with malignant effusion and from 60 patients with nonmalignant pleural effusion. Pleural effusion concentrations of sB7-H4 were measured using sandwich enzyme-linked immunosorbent assay. Malignant effusion exhibited higher sB7-H4 levels than those in nonmalignant effusion (P < 0.01). Lung cancer patients with pleural effusion sB7-H4 levels below 35.8 ng/ml had a longer overall survival than those with higher levels (P < 0.05). By multivariate analysis, pleural effusion sB7-H4 was an independent prognostic factor in patients with MPE. In conclusion, measurement of sB7-H4 might be a useful diagnostic and prognostic value for MPE patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25636447     DOI: 10.1007/s13277-015-3079-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

1.  Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer.

Authors:  Jingting Jiang; Yibei Zhu; Changping Wu; Yueping Shen; Wenxiang Wei; Lujun Chen; Xiao Zheng; Jing Sun; Binfeng Lu; Xueguang Zhang
Journal:  Cancer Immunol Immunother       Date:  2010-08-20       Impact factor: 6.968

2.  B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.

Authors:  Iris Simon; Shaoqiu Zhuo; Laura Corral; Eleftherios P Diamandis; Mark J Sarno; Robert L Wolfert; Nam W Kim
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

3.  Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma.

Authors:  Ilona Kryczek; Shuang Wei; Gefeng Zhu; Leann Myers; Peter Mottram; Pui Cheng; Lieping Chen; George Coukos; Weiping Zou
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

4.  B7-h4 is highly expressed in ductal and lobular breast cancer.

Authors:  Barbara Tringler; Shaoqiu Zhuo; Glenn Pilkington; Kathleen C Torkko; Meenakshi Singh; M Scott Lucia; David E Heinz; Jackie Papkoff; Kenneth R Shroyer
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

5.  B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.

Authors:  Iris Simon; Dionyssios Katsaros; Irene Rigault de la Longrais; Marco Massobrio; Andreas Scorilas; Nam W Kim; Mark J Sarno; Robert L Wolfert; Eleftherios P Diamandis
Journal:  Gynecol Oncol       Date:  2007-05-11       Impact factor: 5.482

6.  Comparison of six biological markers for the diagnosis of tuberculous pleuritis.

Authors:  Akio Hiraki; Keisuke Aoe; Ryosuke Eda; Tadashi Maeda; Tomoyuki Murakami; Kazuro Sugi; Hiroyasu Takeyama
Journal:  Chest       Date:  2004-03       Impact factor: 9.410

Review 7.  Inhibitory B7-family molecules in the tumour microenvironment.

Authors:  Weiping Zou; Lieping Chen
Journal:  Nat Rev Immunol       Date:  2008-06       Impact factor: 53.106

8.  Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct.

Authors:  Nida S Awadallah; Kenneth R Shroyer; Daniel A Langer; Kathleen C Torkko; Yang K Chen; Joel S Bentz; Jackie Papkoff; Wenhui Liu; S Russell Nash; Raj J Shah
Journal:  Pancreas       Date:  2008-03       Impact factor: 3.327

9.  Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage.

Authors:  R Houston Thompson; Xingxing Zang; Christine M Lohse; Bradley C Leibovich; Susan F Slovin; Victor E Reuter; John C Cheville; Michael L Blute; Paul Russo; Eugene D Kwon; James P Allison
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

10.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.

Authors:  Garnet L Anderson; Martin McIntosh; Lieling Wu; Matt Barnett; Gary Goodman; Jason D Thorpe; Lindsay Bergan; Mark D Thornquist; Nathalie Scholler; Nam Kim; Kathy O'Briant; Charles Drescher; Nicole Urban
Journal:  J Natl Cancer Inst       Date:  2009-12-30       Impact factor: 13.506

View more
  3 in total

1.  Assessment of combined expression of B7-H3 and B7-H4 as prognostic marker in esophageal cancer patients.

Authors:  Lujun Chen; Quanqin Xie; Zhigang Wang; Liangrong Shi; Changping Wu; Jingting Jiang
Journal:  Oncotarget       Date:  2016-11-22

2.  Lung adenocarcinoma patients with malignant pleural effusions in hot adaptive immunity status have a longer overall survival.

Authors:  Cheng-Guang Wu; Ruben Casanova; Fabian Mairinger; Alex Soltermann
Journal:  Front Oncol       Date:  2022-10-04       Impact factor: 5.738

3.  The tissue distribution and significance of B7-H4 in laryngeal carcinoma.

Authors:  Lili Chen; Meihua Jin; Chunshi Li; Yongjun Shang; Qinggao Zhang
Journal:  Oncotarget       Date:  2017-09-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.